Sustained STAT3 activation contributed to tumor progression, aberrant JAK2/STAT3 has been detected in a variety of tumor types, suggesting that STAT3 exhibits promise as a drug target for cancer therapeutics 48. This evidence concerns the gene JAK2 and neoplasm.